Pacific Edge (ASX:PEB,NZE:PEB) said the US Centers for Medicare & Medicaid Services recommended a final "gapfill" price of $1,328.30 for the company's urine test Cxbladder Triage Plus, higher than the draft price of $1,018 proposed in April, according to a Wednesday filing with the Australian bourse.
The final price is expected to become effective from Jan.1, 2026, the filing said.